Q-omics provides the consensus-scored CCDC188 profile across patient tissues and cancer cell-line models. CCDC188 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, CCDC188 is differentially expressed in 11, with the highest sampling consensus in LIHC. Additionally, CCDC188 RNA expression shows 18,232 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and LIHC as cancer lineages where CCDC188 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CCDC188 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CCDC188 survival associations across molecular data types. CCDC188 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CCDC188 RNA expression–survival associations across cancer types. High CCDC188 expression shows unfavorable associations in UVM, OV, KIRC, ACC and UCS, but favorable associations in PAAD. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for CCDC188 RNA expression.
This table summarizes CCDC188 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for CCDC188. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CCDC188 shows lower tumor expression in LUSC, BRCA and LUAD and higher tumor expression in LIHC, KIRC and COAD. The LIHC box plot shows higher CCDC188 RNA expression in tumor versus normal tissue (log2 FC = +0.298, t-test p < 0.001).
This table shows molecular features associated with CCDC188 in patient tissues and cancer cell lines. In patient samples, CCDC188 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, CCDC188 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE.
